PE20090192A1 - Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo - Google Patents
Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitriloInfo
- Publication number
- PE20090192A1 PE20090192A1 PE2007001013A PE2007001013A PE20090192A1 PE 20090192 A1 PE20090192 A1 PE 20090192A1 PE 2007001013 A PE2007001013 A PE 2007001013A PE 2007001013 A PE2007001013 A PE 2007001013A PE 20090192 A1 PE20090192 A1 PE 20090192A1
- Authority
- PE
- Peru
- Prior art keywords
- salt
- morpholin
- indol
- pyridin
- hydroxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- JBVWSGZXZRRFSQ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O JBVWSGZXZRRFSQ-UHFFFAOYSA-N 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76455106P | 2006-02-02 | 2006-02-02 | |
| PCT/SE2007/000086 WO2007089191A1 (en) | 2006-02-02 | 2007-01-31 | New citrate salt of an indole derivative and its pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090192A1 true PE20090192A1 (es) | 2009-03-20 |
Family
ID=38327680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001013A PE20090192A1 (es) | 2006-02-02 | 2007-08-02 | Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8008294B2 (OSRAM) |
| EP (1) | EP1981869A4 (OSRAM) |
| JP (1) | JP2009525324A (OSRAM) |
| KR (1) | KR20080098022A (OSRAM) |
| CN (2) | CN101379053A (OSRAM) |
| AR (1) | AR059225A1 (OSRAM) |
| AU (1) | AU2007210336B2 (OSRAM) |
| BR (1) | BRPI0706745A2 (OSRAM) |
| CA (1) | CA2641900A1 (OSRAM) |
| EC (1) | ECSP088647A (OSRAM) |
| IL (1) | IL192888A0 (OSRAM) |
| MX (1) | MX2008009719A (OSRAM) |
| MY (1) | MY146102A (OSRAM) |
| NO (1) | NO20083784L (OSRAM) |
| NZ (1) | NZ570849A (OSRAM) |
| PE (1) | PE20090192A1 (OSRAM) |
| RU (1) | RU2415137C2 (OSRAM) |
| SA (1) | SA07280004B1 (OSRAM) |
| SG (1) | SG169381A1 (OSRAM) |
| TW (1) | TW200800977A (OSRAM) |
| UA (1) | UA94251C2 (OSRAM) |
| UY (1) | UY30126A1 (OSRAM) |
| WO (1) | WO2007089191A1 (OSRAM) |
| ZA (1) | ZA200806725B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| WO2008130312A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| US20100267720A1 (en) * | 2007-07-30 | 2010-10-21 | Astrazeneca Ab | Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439593C (en) | 2001-04-05 | 2010-02-09 | Torrent Pharmaceuticals Ltd. | Heterocyclic compounds for aging-related and diabetic vascular complications |
| JP2003009588A (ja) | 2001-06-20 | 2003-01-10 | Toshiba Corp | 車両連続運転装置用インバータ装置 |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| US20050054663A1 (en) * | 2003-08-13 | 2005-03-10 | Bennett Christina N. | GSK-3 inhibitors |
| TWI427077B (zh) | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
-
2007
- 2007-01-23 SA SA07280004A patent/SA07280004B1/ar unknown
- 2007-01-29 TW TW096103245A patent/TW200800977A/zh unknown
- 2007-01-29 AR ARP070100366A patent/AR059225A1/es not_active Application Discontinuation
- 2007-01-31 EP EP07709302A patent/EP1981869A4/en not_active Withdrawn
- 2007-01-31 CN CNA2007800041531A patent/CN101379053A/zh active Pending
- 2007-01-31 NZ NZ570849A patent/NZ570849A/en not_active IP Right Cessation
- 2007-01-31 MX MX2008009719A patent/MX2008009719A/es active IP Right Grant
- 2007-01-31 KR KR1020087019047A patent/KR20080098022A/ko not_active Ceased
- 2007-01-31 CN CNA2007800043630A patent/CN101378754A/zh active Pending
- 2007-01-31 BR BRPI0706745-3A patent/BRPI0706745A2/pt not_active IP Right Cessation
- 2007-01-31 JP JP2008553201A patent/JP2009525324A/ja not_active Ceased
- 2007-01-31 WO PCT/SE2007/000086 patent/WO2007089191A1/en not_active Ceased
- 2007-01-31 AU AU2007210336A patent/AU2007210336B2/en not_active Ceased
- 2007-01-31 SG SG201100793-7A patent/SG169381A1/en unknown
- 2007-01-31 RU RU2008131906/04A patent/RU2415137C2/ru not_active IP Right Cessation
- 2007-01-31 CA CA002641900A patent/CA2641900A1/en not_active Abandoned
- 2007-01-31 US US12/162,540 patent/US8008294B2/en not_active Expired - Fee Related
- 2007-01-31 UY UY30126A patent/UY30126A1/es not_active Application Discontinuation
- 2007-01-31 UA UAA200809265A patent/UA94251C2/ru unknown
- 2007-01-31 MY MYPI20082900A patent/MY146102A/en unknown
- 2007-02-02 US US11/670,681 patent/US20070203137A1/en not_active Abandoned
- 2007-08-02 PE PE2007001013A patent/PE20090192A1/es not_active Application Discontinuation
-
2008
- 2008-07-17 IL IL192888A patent/IL192888A0/en unknown
- 2008-07-24 EC EC2008008647A patent/ECSP088647A/es unknown
- 2008-08-01 ZA ZA200806725A patent/ZA200806725B/xx unknown
- 2008-09-02 NO NO20083784A patent/NO20083784L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101378754A (zh) | 2009-03-04 |
| US20070203137A1 (en) | 2007-08-30 |
| MY146102A (en) | 2012-06-29 |
| ECSP088647A (es) | 2008-08-29 |
| IL192888A0 (en) | 2009-02-11 |
| NO20083784L (no) | 2008-10-13 |
| AU2007210336B2 (en) | 2011-03-24 |
| RU2415137C2 (ru) | 2011-03-27 |
| KR20080098022A (ko) | 2008-11-06 |
| CN101379053A (zh) | 2009-03-04 |
| ZA200806725B (en) | 2009-07-29 |
| US20090023732A1 (en) | 2009-01-22 |
| NZ570849A (en) | 2011-01-28 |
| AU2007210336A1 (en) | 2007-08-09 |
| AR059225A1 (es) | 2008-03-19 |
| SG169381A1 (en) | 2011-03-30 |
| JP2009525324A (ja) | 2009-07-09 |
| SA07280004B1 (ar) | 2011-10-29 |
| UY30126A1 (es) | 2007-09-28 |
| UA94251C2 (ru) | 2011-04-26 |
| RU2008131906A (ru) | 2010-03-10 |
| TW200800977A (en) | 2008-01-01 |
| CA2641900A1 (en) | 2007-08-09 |
| BRPI0706745A2 (pt) | 2011-04-05 |
| EP1981869A1 (en) | 2008-10-22 |
| MX2008009719A (es) | 2008-09-04 |
| US8008294B2 (en) | 2011-08-30 |
| EP1981869A4 (en) | 2010-08-25 |
| WO2007089191A1 (en) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090192A1 (es) | Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo | |
| TW200626068A (en) | Active compounds for seed treatment | |
| WO2007058583A3 (en) | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | |
| PE20121337A1 (es) | Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa | |
| PL2311805T3 (pl) | Nowa postać polimorficzna octanu bazedoksyfenu | |
| EA201070001A1 (ru) | Водная композиция, содержащая соль, способ её получения и применения | |
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| WO2007070504A3 (en) | Stable and palatable oral liquid sumatriptan compositions | |
| NO20072290L (no) | Organiske forbindelser. | |
| WO2003070731A3 (en) | Azabicyclic compounds for the treatment of disease | |
| WO2008050199A8 (en) | Substituted phenylmethyl bicyclocarboxyamide compounds | |
| PE20030923A1 (es) | Forma polimorfica cristalina de clorhidrato de irinotecan | |
| EA200900732A1 (ru) | Кристаллическая калиевая соль аналогов липоксина а | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
| BR112016011632A2 (pt) | Método para sintetizar um derivado de porfirina, método para sintetizar um composto, método para sintetizar um composto hidrato, método de síntese, recipiente compreendendo uma pluralidade de compostos, formulação farmacêutica, método para purificar um composto, cristal, e, forma cristalina de complexo [5,10,15,20-tetrakis(1,3-dietilimidazólio-2-il)porfirinato]manganês(iii) cloreto hidrato | |
| ECSP055859A (es) | Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| PE20080134A1 (es) | Sal nitrato de alisquireno | |
| GEP20125680B (en) | Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation | |
| NO20073602L (no) | Fremgangsmate for fremstilling av hoyrent meloksikam og meloksikamkaliumsalt | |
| JOP20190279A1 (ar) | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة | |
| TW200833708A (en) | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| IL206032A0 (en) | Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester | |
| WO2007032009A3 (en) | Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |